It will be interesting to see if global biopharma companies continue to in-license Chinese assets at their current rate (roughly one third of all in-licensing was for assets developed by Chinese companies in 2024). The new US FDA leadership certainly recognises the limitations of the current regulatory structure so it’s possible that they will address these problems.
Totally agree, Saul. The fact that about a third of in-licensing came from Chinese companies last year really shows how fast things are shifting. I’m also curious how the FDA will approach this under the new leadership. Hopefully there’s room to modernize the system without closing doors to global innovation.
Good stuff BB! Seems like the US Government is also taking the Chinese advancements in Biotechnology seriously (https://breakingdefense.com/2025/04/congressional-biotech-commission-calls-for-15b-over-5-years-to-catch-up-to-china/)...finally.
And taking up more public/private partnerships - early days for sure - but will be interesting to keep an eye on (https://www.biotech.senate.gov/press-releases/government-leaders-call-for-expanded-biotech-workforce-development-private-public-partnerships-to-unleash-biotechnology-innovation/).
It will be interesting to see if global biopharma companies continue to in-license Chinese assets at their current rate (roughly one third of all in-licensing was for assets developed by Chinese companies in 2024). The new US FDA leadership certainly recognises the limitations of the current regulatory structure so it’s possible that they will address these problems.
Totally agree, Saul. The fact that about a third of in-licensing came from Chinese companies last year really shows how fast things are shifting. I’m also curious how the FDA will approach this under the new leadership. Hopefully there’s room to modernize the system without closing doors to global innovation.